NIG
IOVA icon

NFJ Investment Group’s Iovance Biotherapeutics IOVA Stock Holding History

NFJ Investment Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-187,342
Closed -$624K – 289
2025
Q1 		$624K Hold
187,342
– – 0.02% 254
2024
Q4 		$1.39M Sell
187,342
-2,313
-1% -$21.4K 0.04% 235
2024
Q3 		$1.78M Sell
189,655
-8,775
-4% -$83.1K 0.05% 221
2024
Q2 		$1.59M Sell
198,430
-13,726
-6% -$147K 0.05% 208
2024
Q1 		$3.14M Sell
212,156
-589
-0.3% -$6.86K 0.09% 172
2023
Q4 		$1.73M Buy
+212,745
New +$1.11M 0.05% 191

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

NFJ Investment Group's IOVA Position: Q2 2025 in Review

NFJ Investment Group sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 187,342 shares — an estimated $624K sold.

NFJ Investment Group first reported a position in IOVA in Q4 2023 and held it in 6 quarters. The position peaked at $3.14M in Q1 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • NFJ Investment Group reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • NFJ Investment Group sold 187,342 Iovance Biotherapeutics shares in Q2 2025, an estimated $624K.
  • NFJ Investment Group first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 6 quarters.
  • NFJ Investment Group's Iovance Biotherapeutics position peaked at $3.14M in Q1 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on NFJ Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.